---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-018617"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:50:52.283067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports positive interim Phase 1/2 data for PBGM01 in GM1 gangliosidosis

## Summary
- No treatment-related SAEs; all AEs mild-moderate; no DRG toxicity or ICM administration complications.
- Dose-dependent CSF β-Gal activity increases (up to 5.2-fold) and GM1 ganglioside decreases (up to 75%) in high-dose cohort.
- Patients with milder baseline developmental delay showed meaningful improvement on Vineland and Bayley scales.
- Cohort 4 fully dosed; data expected by mid-2023; conference call held December 14, 2022.

## SEC filing metadata
- accession: 0001558370-22-018617
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837022018617/0001558370-22-018617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837022018617/pasg-20221214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-018617
- JSON: https://secwatch.observer/filing/0001558370-22-018617.json
- Plain text: https://secwatch.observer/filing/0001558370-22-018617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.